Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Effectiveness of XR-Naltrexone vs. Buprenorphine: Results of Two Randomized Trials (1 CME)

    Product not yet rated Contains 4 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning about the only head-to-head randomized trials comparing buprenorphine to XR-naltrexone from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.0 CME) In this conference recording from the 2018 Annual Conference, you will learn about he only head-to-head randomized trials comparing buprenorphine to XR-naltrexone. Opioid use disorders are a major public health problem across North America and many other parts of the world with increasing prevalence and mortality from overdoses. Effective medications exist, including agonist substitution strategies with the full agonist methadone and partial agonist buprenorphine. The antagonist naltrexone was of limited effectiveness when only available in pill form due to poor adherence, but long-acting injectable naltrexone, as well as long-acting implants in some countries, have shown clear effectiveness compared to counseling without medication, placebo, or oral naltrexone. Thus, clinicians and their patients with opioid use disorder now have a choice between medications with distinct mechanisms of action—agonist or antagonist. However, there have been no head-to-head trials comparing these two approaches and informing patient-treatment matching, or helping clinicians and patients judge which medication would be best for an individual patient. Two independently conducted randomized controlled trials concluded in 2016-2017, and each compared extended-release naltrexone monthly injections to buprenorphine-naloxone film daily self-administration for the prevention of heroin/opioid use and relapse among adults initially admitted to inpatient detoxification units and discharged to outpatient management. 

    The NIDA Clinical Trials Network 0051 Study, X:BOT, was an 8-site 24-week RCT among N=570 participants estimating rates of a primary opioid relapse outcome by arm. In Norway, a 5-site 12-week RCT among N=164 participants, sponsored by the Research Council of Norway, included a primary non-inferiority comparison of rates of (non-buprenorphine) opioid use and treatment retention. This focused session will present the designs and main results from the two randomized, comparative effectiveness trials of extended-release naltrexone versus buprenorphine-naloxone; Lee and Rotrosen will present X:BOT main results, Tanum those of the Norwegian trial. Secondary analyses of overdose outcomes, patient matching and moderators of medication effectiveness, and important similarities and contrasts between the two trials’ methods and results will be summarized in third presentation by Nunes. The presenters will lead a concluding panel and audience discussion of the findings and implications for community practice, both in the US and Norway. Questions will be encouraged throughout the session, following each presentation.

    Joshua D. Lee

    MD, MSc, FASAM

    Joshua D. Lee MD, MSc is an Associate Professor in the Departments of Population Health and Medicine at the NYU School of Medicine. He is board-certified in Internal Medicine and Addiction Medicine and is a physician at Bellevue Hospital Center, NYU Langone Medical Center, and in the NYC jails. He directs the NYU ABAM Fellowship in Addiction Medicine. His research focuses on novel and medication treatments for addiction among criminal justice and primary care populations.

    John Rotrosen

    MD

    Dr. Rotrosen is Professor of Psychiatry at New York University School of Medicine. He attended NYU School of Medicine from 1968 to 1972 and completed a Psychiatry Research Residency at NYU and Bellevue Hospital in 1976. Subsequent research training was supported in part by an NIMH Research Scientist Career Development Award under the mentorship of Drs. Samuel Gershon and Burt Angrist. From 1980 through 1997, he served as Chief, Psychiatry Service, and from 1997 to 2013, as Associate Chief of Staff for Mental Health Research at the VA Medical Center in New York. His research has focused on addictive disorders, attention deficit hyperactivity disorder and schizophrenia and movement disorders, addressing pathophysiology, pharmacological and behavioral intervention, and translation to community settings. His research group has contributed to the development of many of the atypical antipsychotic agents and to the development of new medications, novel forms of medication delivery, and behavioral therapies for opiate, cocaine, alcohol and nicotine dependence. He was PI of the NY VAMC-based NIDA/VA Medications Development Research Unit from 1995-2001 and PI of the NY Node of the NIDA Clinical Trials Network (and currently one of the two PIs of the merged Greater NY Node). He recently served on the National Advisory Council on Drug Abuse (NIDA Council) and previously on NIMH Council. Current work in addictive disorders includes studies on clinical genetics, neuroimaging, medication and behavioral therapies development, implementation in mainstream healthcare settings, services and healthcare disparities, and practice improvement. He chairs and serves as a member of data monitoring and safety boards and as a medical monitor for several studies and serves as a key mentor to a multi-disciplinary group of trainees, K-awardees and junior faculty.

    Edward Nunes

    MD

    Dr. Nunes is a Professor of Psychiatry, and Principal Investigator of the Greater New York Node of the National Institute on Drug Abuse (NIDA) clinical Trials Network as well as other NIDA funded studies on behavioral and medication treatments for substance dependence and related psychiatric disorders. Interests and ongoing studies include treatments for cocaine dependence in general, heroin and other opioid dependence, for nicotine dependence in general, and for addicted patients with co-occurring psychiatric disorders including depression, and post-traumatic stress disorder. Types of treatment under study include medication treatments (naltrexone, buprenorphine, mirtazapine) as well as behavioral and psychotherapeutic approaches and computer-delivered treatments. Dr. Nunes also studies the challenges involved in implementing evidence-based treatments for substance use disorders in real-world community-based treatments settings. Dr. Nunes also serves on the American Board of Addiction Medicine, Co-Chair of the Columbia/ New York State Psychiatric Institute's Institutional Review Board, and has been appointed to the National Advisory Council on Drug Abuse.

    Lars Tanum

    PhD

    Lars Tanum, M.D., Ph.D., is an Associate Professor, Norwegian Centre for Addiction Research at the University of Oslo, Norway, and Head of Research Unit, Department of R&D in Mental Health Services, Akershus University Hospital, Norway. 

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

  • Primary Care Based Recovery Coaching and SUD Pharmacotherapy Reduces Hospital Utilization (1 CME)

    Product not yet rated Contains 4 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning how to implement primary care based recovery coaches coupled with integrated addiction treatment across four practices affiliated with a large academic medical center and the effect on acute care utilization for patients with substance use disorder from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.0 CME) In this conference recording from the 2018 Annual Conference, you will learn that substance use disorder (SUD) results in tremendous healthcare costs. Several components of SUD treatment have been shown to reduce inpatient and emergency department utilization, including pharmacotherapy and integrated addiction and primary care for individuals with substance-related medical conditions. 

    No studies have examined the impact of integrated addiction treatment in primary care, which includes recovery coaches in addition to pharmacotherapy, on utilization.Intervention: We integrated treatment into primary care practices with the formation of multi-disciplinary teams of local champions, access to pharmacotherapy with buprenorphine and extended-release naltrexone, counseling, and recovery coaching. The champion teams met bi-monthly with two addiction specialists for case conferences. Recovery coaches were included in each intervention practice to assist patients through addressing barriers to treatment and providing motivational support. Recovery coaches were required to have two years of sobriety, took a five-day course in recovery coaching, worked full-time within the primary care site, and provided in-person, telephonic and text messaging support to patients.

    Methods: We identified patients with a SUD diagnosis, excluding cannabis or tobacco only, receiving consistent primary care at four practices in a nine-month baseline period prior to the intervention. The starting dates varied from October 2014 to December 2015 depending on site. Baseline was defined as the 9-month period prior to intervention and follow-up period was the same nine calendar months one year after the baseline period. We selected control patients from practices without intervention, matching on: age; race, SUD, Charlson comorbidity score; and similar utilization during baseline period. Matched pairs were compared for utilization during a nine-month follow-up period.Results: There were 1870 patients identified from the intervention practices and 5170 from control practices; 445 matched pairs were found based on the matching criteria. Drug use disorder NOS (received by 77% of patients) was the most common diagnosis, followed by opioid use disorder (55%) and alcohol use disorder (24%). 

    There was an increase in utilization in both groups, however the magnitude of increase was higher in control practices. The mean number of inpatient admissions during the follow-up period was 10.6/100 patients for the intervention and 13.7/100 patients for the control group (p=0.18). The total number of hospital days in the follow-up period was 237 days for the intervention and 328 days for the control group (p=0.0001). The mean number of ED visits during follow-up was 23.8/100 patients for the intervention and 33.5/100 patients for the control group (p=0.007).

    Conclusion: Integrated addiction pharmacotherapy and recovery coaching in primary care resulted in fewer hospital days and ED visits for patients with SUD compared to similarly matched patients in practices without these services.

    Sarah Wakeman

    MD, FASAM

    Sarah E. Wakeman, MD is the Medical Director for the Mass General Hospital Substance Use Disorder Initiative, program director of the Mass General Addiction Medicine fellowship, and an Assistant Professor of Medicine at Harvard Medical School. She is also the Medical Director of the Mass General Hospital Addiction Consult Team, co-chair of the Mass General Opioid Task Force, and clinical lead of the Partners Healthcare Substance Use Disorder Initiative. She is the Medical Director of RIZE Massachusetts, a state-wide, private sector initiative created to build a $50 million fund to implement and evaluate innovative interventions to address the opioid overdose crisis. She received her A.B. from Brown University and her M.D. from Brown Medical School. She completed residency training in internal medicine and served as Chief Medical Resident at Mass General Hospital. She is a diplomate and fellow of the American Board of Addiction Medicine. She is chair of the policy committee for the Massachusetts Society of Addiction Medicine. She served on Massachusetts' Governor Baker’s Opioid Addiction Working Group. Nationally, she is chair of the American Society of Addiction Medicine Drug Court Task Force and serves on their ethics committee.Clinically she provides specialty addiction and general medical care in the inpatient and outpatient setting at Mass General Hospital and the Mass General Charlestown Health Center. Her research interests include evaluating models for integrated substance use disorder treatment in medical settings, recovery coaching, physician attitudes and practice related to substance use disorder, and screening for substance use in primary care.

    Nancy Rigotti

    MD

    Dr. Nancy Rigotti is a primary care physician who trained in internal medicine at Massachusetts General Hospital (MGH), where she is Associate Chief of the Division of General Internal Medicine and a Professor of Medicine at Harvard Medical School.  An internationally-known expert on tobacco use and treatment,  Dr. Rigotti has long advocated for improving the delivery of tobacco dependence treatment in the health care system.  She founded and directs MGH’s Tobacco Research and Treatment Center, which combines a clinical treatment program, the MGH Tobacco Treatment Service, with a multidisciplinary research group that develops, test, and disseminate interventions for smoking cessation across outpatient and inpatient settings.  Working at the junction of medicine and public health, Dr. Rigotti’s work combines efforts to change individual behavior with community, policy, and health care system efforts to influence individuals’ decisions about starting or continuing to smoke.

    Yuchiao Chang

    PhD

    Dr. Chang is a statistician based in the Massachusetts General Hospital Division of General Internal Medicine. As part of this role, Dr. Chang provides biostatistical support for a number of TRTC projects. Additionally, she has collaborated on various grants with investigators from many different specialties. Dr. Chang also supports the research efforts in the Mongan Institute and is involved in many hospital operations improvement projects.

    Dr. Chang participated in the Mass General Clinical Research Program from 1997 to 2001. Through this activity, she provided statistical consultation to the entire Mass General community. Over the years, Dr. Chang has provided extensive formal and informal teaching to her clinical colleagues to improve their understanding of statistical science. A great extent of her effort involves educating fellows about design and analysis issues in their research projects.

    Joshua Metlay

    MD, PhD

    Dr. Metlay received his bachelor's degree from Yale University, his PhD in Immunology from Rockefeller University, and his MD from Cornell University Medical College.  He completed residency and chief residency in internal medicine at the University of Pittsburgh and a fellowship in general internal medicine and epidemiology at the Massachusetts General Hospital.  He also received a Master of Science in Health Policy and Management from the Harvard School of Public Health. 

    Dr. Metlay's research spans two major areas, the epidemiology of drug resistance among common bacterial respiratory pathogens, particularly S. pneumoniae and the development and evaluation of interventions to improve the quality of treatment decisions for respiratory tract infections.  This research has led to numerous federal grants from NIAID, CDC, and AHRQ and roles on national advisory committees in the area of infectious diseases epidemiology.

    Dr. Metlay is dedicated to education and mentorship.  He has been recognized with a number of honors including the Lindback Foundation Award for Distinguished Teaching in 2008 (Pen's highest teaching honor), the Mid-Career Research and Mentorship Award from the Society of General Internal Medicine in 2010, and the Arthur Asbury Outstanding Faculty Mentorship Award from the Perelman School of Medicine at the University of Pennsylvania in 2011. 

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

  • Healthcare & Drug Court Partnerships (1 CME)

    Product not yet rated Contains 4 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning how the court system works, how drug courts operate, and ways to create effective partnerships with criminal justice professionals, from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.0 CME) In this conference recording from the 2018 Annual Conference, you will gain an understanding of how the court system works, how drug courts operate, and ways to create effective partnerships with criminal justice professionals. Specific attention will be directed toward shared clients who need, or are prescribed, Medication Assisted Treatment (MAT). This presentation will give healthcare providers a broad overview of the how the court system works with focused attention given to understanding the operations of drug and sobriety courts. Barriers to effective collaboration with the courts will be discussed (e.g., legal issues, confidentiality concerns, stigma of MAT, etc.) and strategies to navigating these challenges will be shared. Attendees will leave with a firm understanding of how the court system is structured, how drug courts work, and tools to help medical providers more effectively work with the courts and advocate for shared clients who are in need of, or are prescribed, MAT. 

    Persons with an addiction disorder rarely interact with only one healthcare system or provider. Yet coordination and collaboration between healthcare, addiction treatment, and other systems is often poorly executed. As we continue to see death rates increase around the country, it is critical we start building broader systems of care. This presentation will focus on building better coordination between healthcare and criminal justice, with specific focus on drug courts. We will address the importance of dismantling barriers such as concerns about confidentiality and stigma of MAT. We will provide specific strategies for improving collaboration among systems, thus building better and more effective systems of care for individuals suffering from an addiction disorder.

    Michele Virva

    LMSW

    Michele (Shelly) Virva is a licensed master's level social worker, currently working with Dr. Corey Waller at the Spectrum Health Medical Group Center for Integrative Medicine, a specialty clinic for high frequency ED utilizers and pregnant women on controlled substances. Shelly has earned her Bachelors of Arts in political science and a Masters of Social Work from Western Michigan University. She has extensive experience in the treatment of substance use and co-occurring disorders, pregnancy and substance use disorders, crisis intervention, integrated care, and treatment of complex care patients. She has a strong interest in evidenced based treatment, research and system development. Currently, she is working with a private philanthropy in Ca. developing integrated care clinics for high opioid users. Prior to this she was part of a team working on integrating behavioral health into a multisite primary care group. She has worked with a large regional health plan in Michigan to incorporate medication assisted treatment into their benefit structure, and has co-authored the Michigan Medication Assistance Treatment Program Guidelines with Dr. Corey Waller.

    Andrew Brown

    MPA, MSW

    Andy Brown is the Program Coordinator for the Ottawa County Recovery Court located in Michigan. He has served in this position for eight years and holds Masters Degrees in Public Administration and Social Work and is a Fellows with the National Center for State Courts. His recovery court is currently recognized as one of nine national mentor courts in the United States by the US Department of Justice and the National Association of Drug Court Professionals. Andy has a strong desire to build constructive working relationships between the courts and community partners who serve our common clientele.

    Tyson Smith

    PhD

    No Bio Available.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.0 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.0 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Unhealthy Alcohol Use: Update on the Forgotten Epidemic (1.5 CME)

    Product not yet rated Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning how to manage alcohol withdrawal and understand the evidence for the use of pharmacotherapy in the treatment of alcohol use disorder, from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn that/about the epidemic forgotten in light of the opioid epidemic. The prevalence of unhealthy alcohol use appears to be increasing, yet attention to it has not been commensurate with its prevalence and impact on health and society. It seems to be hidden or forgotten. First we will review data (some, conflicting) on the rising prevalence and impact of alcohol use on health, and the role alcohol plays in consequences of other drug use. Next, we will discuss validated approaches for identification, challenges in assessment relevant to general health settings, and initial management. Management of alcohol withdrawal will be reviewed by clinical champions contributing to ASAM's practice guideline revision. We will review the evidence for the 4 FDA approved medications and address the efficacy or lack thereof for others. Finally, we address integrated care management for alcohol use disorder including generalists and addiction specialist roles. The main goal is to review what clinical science tells us about how to care for people with unhealthy alcohol use.

    Richard Saitz

    MD, MPH, DFASAM, FACP

    Richard Saitz MD, MPH, FACP, DFASAM is a general internist (DABIM) and primary care physician, an addiction medicine specialist (DABAM), Chair and Professor of Community Health Sciences at Boston University (BU) School of Public Health, and Professor of Medicine at BU School of Medicine. He Chaired the Treatment and Services review committee for the National Institute on Alcohol Abuse and Alcoholism, is Associate Editor of JAMA and Senior Editor of Journal of Addiction Medicine, Section Editor and sole author of key chapters in UpToDate on unhealthy substance use, an editor of the ASAM Principles of Addiction Medicine, and author of >200 peer-reviewed publications http://profiles.bu.edu/display/151440 http://www.bu.edu/sph/profile/richard-saitz/ He was Director of Boston Medical Center’s Clinical Addiction Research and Education (CARE) Unit for over a decade, has been Chairman of an Institutional Review Board, Associate Director of Clinical Research for BU, President of the Association for Medical Education and Research in Substance Abuse (AMERSA), steering committee member of the Motivational Interviewing Network of Trainers (MINT), and was coordinating committee member of International Network for Brief Intervention for Alcohol and other drug problems (INEBRIA). He is Vice President of the International Society of Addiction Journal Editors (ISAJE). His primary areas of expertise supported by NIH, RWJF, and SAMHSA, are screening and brief intervention, integrating substance-related and general health care, improving the quality of care for people with unhealthy substance use, particularly in general health settings, and basing care on science. He validated single-item screening questions recommended by NIDA and NIAAA. Awards: Alpha Omega Alpha Honor Society, Boston Jaycees Ten Outstanding Young Leaders Award, Best Doctors in America®, AMERSA’s W. Anderson Spickard, Jr. Excellence in Mentorship Award, the R. Brinkley Smithers Distinguished Scientist Award (ASAM), Research Society on Alcoholism Distinguished Researcher Award.

    Darius Rastegar

    MD

    Dr. Rastegar provides treatment for substance use disorders in an outpatient primary care setting and an inpatient unit.  He is an Associate Professor of Medicine at Johns Hopkins University School of Medicine and is the medical director for the Chemical Dependence Unit at Johns Hopkins Bayview Medical Center.  He is the co-author of The ASAM Handbook of Addiction Medicine.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Lifelong Learning: Review of Articles for Addiction Medicine Tmoc Part 2 (1 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1 AMA PRA Category 1 Credit(s)™ while learning how to use Tmoc for professional development from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.0 CME) In this conference recording from the 2018 Annual Conference, you will learn that Transitional Maintenance of Certification (Tmoc) is a fundamental part of Addiction Medicine certification for current ABAM Diplomates, and it can be important for patient care as well as professional development. Tmoc Part 2 (also known as Lifelong Learning and Self-Assessment) involves reading medical literature and answering questions based on articles, which is not always easy, especially for new or busy addiction medicine certified physicians. This workshop will help meet Tmoc Part 2 requirements for attendees who are certified in Addiction Medicine. Attendees who are not certified in addiction medicine can still learn about recent research from across the spectrum of the field of Addiction Medicine. This information will be discussed in terms of clinical relevance to patient care. Several new articles from the SAMs will be described and discussed by experienced researcher-educators in Addiction Medicine from around the United States in an unbiased fashion, with attention paid to both strengths and limitations of each article. Conclusions: Participants will gain an appreciation of the scope of recent research in Addiction Medicine and how it may impact patient care. In addition, participants will learn about new research that may potentially affect their practice. Addiction Medicine certified physicians who attend and are participating in Tmoc will be able to answer Part 2 Self-Assessment Module questions for Tmoc credit during this workshop.

    Michael Fingerhood

    MD, FACP

    Dr. Michael Fingerhood is an Associate Professor of Medicine at the Johns Hopkins University. He is the Chief of the Division of Chemical Dependence and medical director of the Comprehensive Care Practice (CCP) at Johns Hopkins Bayview Medical Center. The CCP integrates substance abuse treatment with primary medical care, including care for HIV and hepatitis C.

    Gavin Bart

    MD, PhD, FACP, DFASAM

    Dr. Gavin Bart is Director of the Division of Addiction Medicine at Hennepin County Medical Center and Associate Professor of Medicine at the University of Minnesota. He received his MD from the University of Minnesota and trained in internal medicine at the Hennepin County Medical Center. His PhD is in experimental and clinical pharmacology, also from the University of Minnesota. He trained in addiction medicine at The Rockefeller University where he continued as Director of Clinical Research until moving to Minnesota where is is co-PI of the NorthStar Node of the NIDA Clinical Trials Network. His areas of expertise include clinical pharmacology and the pharmacological management of opioid dependence. 

    His current research areas include the population pharmacokinetics of methadone, genetic influences of methadone pharmacology and treatment outcome, electronic health record privacy provisions of 42 CFR Part 2, and clinical decision support tool development for SUD. 

    He is Chair of the Life-Long Learning and Self-Assessment committee for the American Board of Addiction Medicine and is ASAM Region VI (IA, IL, IN, MI, MN, WI) director. Internationally, he is co-director of the SAMHSA-funded Vietnam HIV and Addiction Technology Transfer Center and provides ongoing technical assistance for the Substance Abuse and Mental Health Administration in South East and Central Asia.

    Alexander Y. Walley

    MD, MSc, FASAM

    Alexander Y. Walley, M.D., M.Sc., is an Associate Professor of Medicine at Boston University School of Medicine, a general internist and addiction medicine specialist at Boston Medical Center. He is the director of the Addiction Medicine Fellowship program and founded the Inpatient Addiction Consult Service at Boston Medical Center. He does clinical and research-related work on the medical complications of substance use, specifically HIV and overdose. He provides primary care and office-based buprenorphine treatment for HIV patients and methadone maintenance treatment. He is the medical director for the Massachusetts Department of Public Health’s Opioid Overdose Prevention Pilot Program. 

    Lia Bennett

    MPH

    Lia Bennett is an independent consultant serving as the Director of Maintenance of Certification for the American Board of Addiction. She was a quality improvement program coordinator for the American College of Physicians and brings to ABAM, over 10 years of experience developing and managing MOC compliant programs. She has worked in the field of internal medicine conducting continuing medical education research in the areas of adult immunization, cardiovascular risk and diabetes. Ms. Bennett received her Masters of Public Health with a graduate certificate in Integrative Health. She strives to provide superior guidance to ABAM Diplomates.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of AMA PRA Category 1 Credit(s)™ for completing this course.

  • Hepatitis C Prevention, Management and Treatment for Addiction Medicine Practitioners (1.5 CME)

    Product not yet rated Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ , while learning how to summarize and describe CDCs Hepatitis C testing and treatment guidelines, and describe successful models of programs in opioid substitution treatment programs and addiction treatment centers, from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.5CME) In this conference recording from the 2018 Annual Conference, you will learn that, globally, hepatitis C virus (HCV) infection is a major health issue among people who inject drugs (PWID). Within 1 year of injecting drugs, 1 of 3 individuals will become infected with HCV. Overall, 70 to 77% of PWID are HCV positive. There is a growing burden of HCV-related cirrhosis, liver cancer, and liver-related mortality, particularly among those infected for many decades. Perhaps even more concerning is the growing number of younger individuals newly infected with HCV through injection opiate use (Zibbell, 2014) (Colvin, 2010). 

    The advent of simple and well-tolerated oral HCV therapeutic regimens – direct-acting antivirals (DAAs) – with cure >95% has the potential to reverse the rising tide of advanced liver disease and with cure, prevent disease transmission (Grebely, 2017). These effective DAAs have eliminated interferon as a major barrier to HCV scale-up in PWID. 

    However, in order for these therapies to have an effect at a population-level, targeted interventions to enhance HCV testing, linkage to care, and treatment are needed. The reluctance to offer HCV therapy to PWID often still stems from concerns around treatment adherence, poorer outcomes, and the potential risk for HCV reinfection (Grebely, 2017). This reluctance exists despite growing evidence that HCV can be successfully treated among active drug users (Muething, 2015). 

    Furthermore, stigma and judgement regarding drug use and addiction among traditional HCV treaters has led to mistrust and reluctance to seek care by providers (Feller, 2013). This workshop will review the epidemiology of HCV among PWID, and effective strategies to enhance HCV testing, linkage to care and treatment for PWID. A particular focus will be given to the role of addiction medicine practitioners in preventing and treating HCV, especially in substance treatment facilities.

    Alain H. Litwin

    MD, MPH

    Alain Litwin, MD, MPH is Vice Chair of Academics and Research and Professor of Medicine at Greenville Health System, University of South Carolina School of Medicine – Greenville, and Clemson University School of Health Research where he is launching a Center for Addiction and Prevention Research.  He is board certified in internal medicine and addiction medicine, and has been providing medical care to people who use drugs with complex social, psychiatric and medical needs within an integrated primary care and substance use treatment program since 2000. As HCV Medical Director at Albert Einstein’s Division of Substance Abuse, he developed a comprehensive on-site HCV treatment program and peer educator program to improve medical care of HCV-infected people who use drugs. As HCV Treatment Network Director at Montefiore Medical Center, he expanded patient-centered models of care at many community health centers serving thousands of HCV-infected people throughout the Bronx.  With funding from NIH, PCORI, CMS, CDC, AHRQ, the Robert Wood Johnson Foundation, New York State Department of Health, New York City Department of Health, and industry, Dr. Litwin’s research has been focused on developing and studying models of HCV care, and on advocating for increasing access to effective care for all HCV-infected patients.  Dr. Litwin has worked with government and community organizations on efforts to expand access to HCV treatment and has collaborated on policy statements, clinical guidelines, treatment improvement protocols, task forces, and educational curricula with the New York City Department of Health and Mental Hygiene, New York State Department of Health, Substance Abuse and Mental Health Service Administration, Center for Substance Abuse Treatment, American Association for the Treatment of Opioid Dependence, and the American Society of Addiction Medicine.  Dr. Litwin serves on the Executive Board for the International Network on Hepatitis in Substance Users (INHSU).

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Opening Scientific Plenary & Distinguished Scientist Lecture (1.5 CME)

    Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while you learn about the incredible impact addiction medicine providers can have on an individual, policy, and the future of treatment and science, from this conference recording at The ASAM 49th Annual Conference (2018). This session was made available free of charge by ASAM.

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will be energized as Dr. Kelly J. Clark, MD, MBA, DFASAM, leads the Opening Scientific Plenary Session, focusing on the incredible impact addiction medicine providers can have on an individual, policy, and the future of treatment and science.

    Elinore F. McCance-Katz

    MD, PhD

    Elinore F. McCance-Katz, MD, PhD, is the first Assistant Secretary for Mental Health and Substance Use. She advises the Health and Human Services (HHS) Secretary on improving behavioral healthcare in America and leads the Substance Abuse and Mental Health Services Administration (SAMHSA), an agency responding to the nation’s opioid crisis. Dr. McCance-Katz fervently supports evidence-based early intervention, treatment, and recovery services for people who have mental health and substance use disorders. Dr. McCance-Katz has more than 25 years of experience as a clinician, teacher, and researcher.

    Michael E. Charness

    MD

    Michael E. Charness, MD, became Chief of Staff for the VA Boston Healthcare System in 2003. His laboratory, with support from the National Institutes of Health (NIH) and the VA, studies the mechanisms of alcohol toxicity in the nervous system and the development of drugs that block alcohol toxicity. Dr. Charness is scientific director of the NIAAA-funded Collaborative Initiative on Fetal Alcohol Spectrum Disorders, and chairs the external advisory board for the NIH-funded Adolescent Brain and Cognitive Development (ABCD) study. He has cared for patients with neurological complications of alcohol use disorder and peripheral nerve disorders throughout his career.

    Judy Collins

    Singer/Songwriter, Musician

    Judy Collins is a modern-day renaissance woman who is also an accomplished songwriter, painter, filmmaker, record label head, musical mentor, and a high-demand speaker for mental health and addiction. She will share her story about addiction, personal triumph, how an addiction doctor helped her understand for the first time that she had a disease, and how she could get help and change her life. Ms. Collins continues to inspire audiences with sublime vocals, boldly vulnerable songwriting, and music of hope and healing that speaks to the heart.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Opioid and Alcohol Use Disorders in Older Adults: Working Group Guideline Development (1.5 CME)

    Product not yet rated Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning about methods used to review literature on the assessment and treatment of alcohol and opioid use disorders in older adults from this conference recording at The ASAM 49th Annual Conference (2018).

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn how alcohol has now surpassed tobacco as the leading cause of hospital admission in some Canadian provinces, yet alcohol use disorders among those 65 and older often go unidentified and untreated. In addition, older adults are over-represented among Canadians who have had fatal or non-fatal opioid overdoses , yet identification and treatment of opioid use disorders as well as appropriate use of opioids for chronic non-cancer pain remain a challenge for many clinicians. 

    The Canadian Coalition for Seniors Mental Health (CCSMH) has been tasked by Health Canada to develop guidelines for the assessment and treatment of four substance use disorders in older adults (alcohol, opioids, cannabis, and benzodiazepines). As part of guideline development, input is needed from peers working and researching in the field. In this interactive workshop Drs. Rieb and Butt will present a brief overview of the methods used to review literature on the assessment and treatment of alcohol and opioid use disorders in older adults, then share draft guidelines developed by the working groups of the CCSMH. Workshop participants will be encouraged to give feedback and share clinical and research findings to augment the guidelines. Physicians, nurse practitioners, counselors, psychologists, researchers, administrators, and older adults in recovery are among those encouraged to attend for a lively discussion.

    Launette Marie Rieb

    MD, MSc, CCFP, FCFP, DABAM, FASAM

    Dr. Launette Rieb is a Clinical Associate Professor in the Department of Family Practice at the University of British Columbia (UBC), Canada. She is a Family Physician and diplomat of The American Board of Addiction Medicine. She did her graduate work in the area of pain physiology. She completed a postgraduate UBC Clinical Scholar's Program in 2015 and a NIDA sponsored Canadian Addiction Medicine Research Fellowship in 2016 resulting in publication on a newly described opioid pain phenomenon - withdrawal-associated injury-site pain (WISP). She has also published on fentanyl and heroin overdose deaths in BC, as well as on addiction in a variety of marginalized populations. Dr. Rieb is the Medical Director of a multidisciplinary team at OrionHealth (Vancouver Pain Clinic), and works as a consultant for the Rapid Access Addictions Clinic at St. Paul’s Hospital in Vancouver. In addition, she does addiction medicine consultations for The Orchard Recovery Centre, on Bowen Island. Dr. Rieb has taught addiction medicine in the undergraduate and postgraduate medical programs at UBC, and at national and international conferences for 24 years. Dr. Rieb was the co-creator and initial Physician Director of the St. Paul’s Hospital Goldcorp Addiction Medicine Fellowship (now the BC Centre on Substance Use Addiction Medicine Fellowship). She is a member of the Canadian Society of Addiction Medicine’s Education Committee and the College of Family Physician of Canada's Competency Creation Working Group for the Certificate of Added Competency in Addiction Medicine. Dr. Rieb is the past recipient of a UBC Faculty of Medicine Post Graduate Teaching Award. 

    Peter R. Butt

    MD, CCFP, FCFP

    Dr. Peter Butt is a graduate of McMaster University and a Certificant and Fellow with the College of Family Physicians of Canada.  He is an Associate Professor in the Department of Family Medicine at the University of Saskatchewan in a position dedicated to Addiction Medicine, and serves as a consultant to Mental Health and Addictions in the Saskatoon Health Region.  National committee work includes the National Alcohol Strategy Advisory Committee, chair of the Canadian Alcohol Low Risk Drinking Guidelines Expert Advisory Group, co-chair of the Standard Drink Label Working Group, and member of the National Recovery Advisory Committee for the Canadian Centre on Substance Abuse; and physician lead on the Alcohol Screening, Brief Intervention and Referral project for the College of Family Physicians of Canada.  Provincially he is the physician lead on the Saskatchewan provincial “Take Home Naloxone”project, chairs the Opioid Advisory Committee for the College of Physicians and Surgeons of Saskatchewan, and serves on the Health Canada - First Nation Prescription Drug Abuse Initiative.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Using Alcohol Biomarkers to Guide Pharmacotherapy for Alcohol Use Disorder (1.5 CME)

    Product not yet rated Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while reviewing the evidence for the use of phosphatidylethanol (PEth) and other biomarkers in the treatment of AUDs in persons living with HIV. Interventions will include both behavioral and pharmacological treatments, from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn that clinicians can use several biochemical measurements to objectively assess patients’ current or past alcohol use. However, none of these currently available biomarkers, including measures of various liver enzymes and blood volume, are ideal. Several more experimental markers hold promise for measuring acute alcohol consumption and relapse. These include certain alcohol byproducts, such as phosphatidylethanol, acetaldehyde, ethyl glucuronide (EtG), and fatty acid ethyl esters (FAEE), as well as two measures of sialic acid, a carbohydrate that appears to be altered in alcoholics.

    This symposium will provide an update on the use of alcohol biomarkers in general clinical practice, with special emphasis on:

    1. the use of alcohol biomarkers as a guide to the diagnosis and treatment of AUD in primary care settings; 
    2. the use of phosphatidylethanol (PEth) testing as a guide to treatment in patients with co-occurring HIV/AIDS and AUD; and 
    3. the use of alcohol biosensors to monitor response to treatment in both specialty and non-specialty treatment settings.

    Deidra Y. Roach

    MD

    Dr. Roach has more than 30 years of experience in the field of addiction treatment. She currently serves as a Program Director for the National Institute on Alcohol Abuse and Alcoholism where, among other responsibilities, she manages research portfolios addressing the treatment of co-occurring mental health and alcohol use disorders and alcohol-related HIV/AIDS among women. She also serves on the Interagency Coordinating Committee on Fetal Alcohol Spectrum Disorders (ICCFASD) and the NIH Coordinating Committee for Research on Women’s Health. Dr. Roach chairs the Women Drinking, and Pregnancy Work Group of the ICCFASD.

    Scott H. Stewart

    MD, MS

    Scott H. Stewart, MD, MS, Associate Professor, Division of General Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo. 

    Dr. Stewart is a general internist and adult primary care physician, currently teaching and practicing at the Erie County Medical Center, an academic urban safety-net hospital in Buffalo, NY.   After graduating medical school at Temple University in 1993 and completing Internal Medicine training at the University of Pittsburgh in 1996,Dr. Stewart worked for three years in private practice in the beautiful state of Maine, then returned to academia and completed a health services research fellowship at MUSC in Charleston, SC. He has been on the faculty of MUSC and the University at Buffalo since 2001. Working with experienced mentors at the Charleston Alcohol Research Center at MUSC and Research Institute on Addictions in Buffalo early in his research career helped in melding his long-standing interest in alcohol-related problems with scholarly efforts, leading to NIAAA support. 

    Dr. Stewart believes that objective testing and monitoring is needed to optimize AUD treatment in primary care, similar to other chronic conditions such as diabetes and dyslipidemia. While traditional alcohol consumption biomarkers suffer from limited sensitivity or specificity, and self-report screens are subject to error, relatively newer biomarkers have great potential to guide AUD treatment. Accordingly, a point of my foci has been on the use of carbohydrate-deficient transferrin and newer biomarkers (e.g., blood phosphatidylethanol, ethyl glucuronide) in various patient populations and during alcoholism treatment trials. Dr. Stewart believes biomarker development is a complicated and slow process, but these and other laboratory tests will continue to alter how AUD is detected and monitored in medical settings in the coming years.

    Judith Hahn

    PhD

    Judy Hahn, PhD is an Associate Professor in the HIV, ID, and Global Medicine Division in the Department of Medicine at UCSF. She is an epidemiologist with extensive experience studying the behavioral and biological intersections of substance use and infectious diseases. She is a pioneer in the use of biological markers as objective measures for alcohol use. She has received numerous grant awards from the NIH and has published over 100 manuscripts. 

    She is currently leading studies to examine the safety and cost-benefit ratios of using isoniazid to prevent active TB among HIV/TB co-infected drinkers in Uganda, interventions to improve the safety of INH delivered to this population, as well as using mobile phones and tablets to reduce the harm associated with heavy alcohol use. Judy is also a long-time investigator on the UFO Study of HCV in young persons who inject drugs in San Francisco.

    M. Katherine Jung

    PhD

    M. Katherine Jung, PhD, is the Director of the Division of Metabolism and Health Effects (DMHE) in the National Institute on Alcohol Abuse and Alcoholism (NIAAA). DMHE oversees a portfolio on the role of alcohol on organ damage, and the mechanisms of alcohol’s effect on physiology and pathology. Dr. Jung’s training and research experience are in biochemistry, cell biology, and molecular biology. Her peer-reviewed publications span the the areas of alcohol-induced organ damage, cell biology, cancer biology, and drug discovery. She has a longstanding interest in biomarkers of alcohol consumption and of alcohol-associated organ damage. Dr. Jung co-leads the Wearable Alcohol Biosensor initiative for NIAAA.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.

  • Current Trends of Novel Psychoactive Substance Use and Abuse (1.5 CME)

    Product not yet rated Contains 4 Component(s), Medical Credits Offered

    Earn 1.5 AMA PRA Category 1 Credit(s)™ while learning that there continues to be widespread use of novel psychoactive substances (NPS) with the number of different novel active substances increasing worldwide every year, from this conference recording from The ASAM 49th Annual Conference (2018).

    (1.5 CME) In this conference recording from the 2018 Annual Conference, you will learn there continues to be widespread use of novel psychoactive substances (NPS) with the number of different novel psychoactive substances increasing worldwide every year. Understanding global trends is important as new agents are often used or “piloted” in other countries before they become popular in the United States. 

    Between the years of 2009 and 2016, 739 different NPS were reported by 106 countries to the United Nations Office on Drugs and Crime (UNDOC) (“World Drug Report 2017” 2017). In 2015, the majority of NPS reported to UNODC were synthetic stimulants including cathinones and phenethylamines (36%) and synthetic cannabinoid receptor agonists (32%) (“World Drug Report 2017” 2017) . Equally concerning is the occurrence of “mini epidemics” associated with synthetic drugs leading to hospitalization of multiple users at a time (Monte et al. 2014). 46 clusters of adverse drug events were reported in the US related to synthetic cannabinoid receptor agonists between 2012 and 2015 (Trecki, Gerona, and Schwartz 2015). 

    Yet, identifying the drugs responsible for these “mini-epidemics” is often challenging due to the challenges involved with laboratory testing. Indeed patients in treatment for substance use disorders may be using NPS particularly due to the difficulty in detection (Wiegand 2015) as development of laboratory assays cannot keep up with the development of new substances, and cost of testing may be prohibitive to substance use disorder treatment centers. 

    Recognition of use of NPS is thus often based on clinical evaluation (Ninnemann et al. 2016), and best practices for treatment of acute toxicity or chronic use are not well defined (Monte et al. 2017; Ninnemann et al. 2016). It is important for providers in the field of addiction to understand the evolution of novel psychoactive substances, who is using them, signs and treatment of acute toxicity, available laboratory testing, and what is known about long-term sequelae from use of these agents including the potential for addictive disorders (Montanari et al. 2017) and withdrawal in chronic use (Nacca et al. 2013). This knowledge will allow providers to identify and manage patients at risk from complications of use of these substances.

    JoAn Laes

    MD

    JoAn Laes, MD, Attending Physician, Division of Addiction Medicine, Hennepin County Medical Center, Minneapolis, MN; Core Medical Toxicology Faculty, Minnesota Poison Control System, Minneapolis, MN; Medical Director, Mission Detox Center, Plymouth, MN and 1800 Detox, Minneapolis, MN, ASAM Medical Toxicology workgroup Chair.Dr. Laes' practice is focused on inpatient addiction medicine and toxicology consultation and outpatient treatment of opioid and other substance use disorders. She is board certified in Internal Medicine, Addiction Medicine, and Medical Toxicology. She completed internal medicine residency at Hennepin County Medical Center and medical toxicology fellowship at Regions Hospital in St. Paul, Minnesota.

    Christine Murphy

    MD

    Dr. Christine Murphy is an Associate Professor in Emergency Medicine and Medical Toxicologist at Carolinas Healthcare System in Charlotte, North Carolina. Dr. Murphy is the Director for the Medical Toxicology Fellowship Program. She received both her bachelor’s and master’s degrees in chemistry from the College of William and Mary and her medical degree from the Medical College of Virginia. She completed her residency training in Emergency Medicine at Virginia Commonwealth University and a fellowship in Medical Toxicology at Carolinas Medical Center. Dr. Murphy is board certified in Emergency Medicine, Medical Toxicology, and Addiction Medicine. Her current research interests include alternative uses for existing antidotes, pediatric addiction, and trends in recreational drugs of abuse.

    Matthew Peter Stripp

    MD

    Dr. Matthew Stripp is a Junior Faculty Member in Emergency Medicine and a Medical Toxicology Fellow at Carolinas Healthcare System in Charlotte, NC. He received his BA in Cell/Molecular Biology with an emphasis in Neuroscience at Washington & Jefferson College in Washington, PA. He received his medical degree at Temple University School of Medicine in Philadelphia, PA. He completed his residency training in Emergency Medicine at Northwell Health in Manhasset, NY. Dr. Stripp is board certified in Emergency Medicine. His current research interests include mushroom toxicity, synthetic cannabinoids, and other emerging drugs of abuse.

    ACCME Accredited with Commendation

    ACCME Accreditation Statement

    The American Society of Addiction Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    AMA Credit Designation Statement

    The American Society of Addiction Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s).  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    ABPM Maintenance of Certification (MOC)

    The American Board of Preventive Medicine (ABPM) has approved this activity for a maximum of 1.5 LLSA credits towards ABPM MOC Part II requirements.

    ABAM Transitional Maintenance of Certification (tMOC)

    This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Transitional Maintenance of Certification Program (tMOC) can apply a maximum of 1.5 AMA PRA Category 1 Credit(s)™ for completing this course.